,90 Activated KRAS, a well-known oncogenic driver for various tumors, such as pancreatic ductal adenocarcinoma (PDAC) and colon adenocarcinoma (COAD),91,92 enhances cNADK enzyme activity via PKC, boosting NADP+ generation and promoting PDAC progression.90 Here, KRAS is linked to colon adenocarcinoma.